Peter Armstrong Thompson

Title: Peter Armstrong Thompson: Innovator in Immunotherapy

Introduction

Peter Armstrong Thompson is a notable inventor based in Bellevue, WA (US), recognized for his significant contributions to the field of immunotherapy. With a total of nine patents to his name, Thompson has made strides in developing innovative treatments for various diseases, particularly those associated with tumor necrosis factor and B-cell activity.

Latest Patents

Thompson's latest patents include groundbreaking work on humanized anti-tumor necrosis factor alpha receptor 2 (anti-TNFR2) antibodies. This invention provides compositions of anti-TNFR2 antibodies and methods for their preparation and use, particularly in eliciting an immune response against tumors. Additionally, he has developed methods for treating disorders related to TNF and/or TNFR2, including cancer. Another significant patent involves CD37 immunotherapeutics, which outlines methods for B-cell reduction using CD37-specific binding molecules. This invention offers innovative approaches to treating diseases characterized by aberrant B-cell activity.

Career Highlights

Throughout his career, Thompson has worked with prominent companies in the biotechnology sector, including Emergent Product Development Seattle, LLC and Aptevo Research and Development LLC. His work in these organizations has contributed to the advancement of therapeutic solutions in immunology.

Collaborations

Thompson has collaborated with esteemed colleagues such as Jeffrey A. Ledbetter and Martha Susan Hayden-Ledbetter, further enhancing the impact of his research and innovations in the field.

Conclusion

Peter Armstrong Thompson stands out as a leading inventor in immunotherapy, with a focus on developing effective treatments for cancer and other diseases. His contributions through patents and collaborations continue to shape the future of medical science.